Active, not recruiting
- Dec 19, 2019

NCT04045795: Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT04045795: Phase 1: Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

f isatuximab administered subcutaneously (SC)

NCT04045795: Phase 1: Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV)
To assess the safety and tolerability (including local injection site tolerability) of isatuximab using the (investigational) isatuximab injector device.
To evaluate the pharmacokinetics (PK) of SC and IV isatuximab

Sponsor

Sanofi

ClinicalTrials.gov Identifier: NCT05405166

Official Title: A Multi-center, Open-label, Phase 1b Study to Assess the Pharmacokinetics, Safety, and Efficacy of Subcutaneous and Intravenous Isatuximab (SAR650984) in Combination With Pomalidomide and Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

First Posted : August 6, 2019

Click here to see details on ClinicalTrials.gov

Isatuximab : National Cancer Institute

Isatuximab : MedlinePlus Drug Information

Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information

Pomalidomide : National Cancer Institute

Pomalidomide : MedlinePlus Drug Information

Drug: isatuximab SAR650984 IV

Drug: pomalidomide

Drug: dexamethasone

Drug: isatuximab SAR650984 SC